Highlights

  • Proteomics International (ASX:PIQ) was trading at AUD 0.16, up 6.45% (+AUD 0.010) during the morning Trading session on 13 August 2026.
  • IP Australia has issued a notice of acceptance for Patent protection covering the PromarkerEndo endometriosis diagnostic blood test.
  • The patent covers methods using specific protein biomarkers from blood samples to support endometriosis diagnosis and treatment guidance.
  • Patent protection for PromarkerEndo has now advanced in Australia, Japan and the United States.
  • The company continues pursuing patent protection across additional jurisdictions including Canada, China, Europe, India, Singapore and South Korea.

Proteomics International Laboratories Ltd (ASX:PIQ) has secured a key intellectual property milestone for its PromarkerEndo diagnostic technology after receiving a notice of acceptance from IP Australia for its patent application covering the endometriosis blood test.

The patent acceptance provides protection for the company’s proprietary diagnostic technology in Australia, supporting Proteomics International’s commercialisation pathway for PromarkerEndo and potential future Partnership and licensing opportunities.

Proteomics International was trading at AUD 0.16, up 6.45% (+AUD 0.010) during the morning trading session on 13 August 2026, while the stock remains down 54.17% (-AUD 0.19) over the past year.

Australian Patent Milestone for PromarkerEndo

The accepted patent application covers methods for diagnosing endometriosis using specific protein biomarkers measured from blood samples, with results also used to guide treatment selection.

Proteomics International said the patent strengthens its intellectual property portfolio and represents progress towards securing broader patent protection across healthcare markets.

Subject to grant and maintenance requirements, the Australian patent protection is expected to extend until March 2041.

The company stated that securing protection in Australia represents an important step given the country’s role in its commercialisation plans for PromarkerEndo.

Diagnostic Technology Targets Endometriosis Detection

PromarkerEndo is a blood-based diagnostic test developed using Proteomics International’s proprietary Promarker biomarker discovery platform.

The technology identifies protein fingerprints within samples to distinguish between individuals with and without a disease. The company uses this approach to develop diagnostic applications based on protein biomarkers rather than genetic testing.

Proteomics International said published clinical data has demonstrated high accuracy for PromarkerEndo in detecting endometriosis, including during early stages of the disease.

The test is being developed to provide a non-invasive diagnostic option that may assist in reducing reliance on invasive surgical procedures for women presenting with symptoms of endometriosis.

Addressing Delays in Endometriosis Diagnosis

Endometriosis affects approximately one in nine women and girls, according to the company.

The current diagnostic pathway typically involves surgical laparoscopy, with diagnosis often taking an average of seven years.

Proteomics International said PromarkerEndo is being developed to address the need for earlier and more accessible diagnosis through a blood-based testing approach.

The company stated that the technology aims to support earlier identification of the condition and provide information that may assist treatment decisions.

Global Patent Expansion Continues

Alongside Australia, Proteomics International has already secured granted patent protection for PromarkerEndo technology in Japan and the United States.

The company is also pursuing patent protection across additional major jurisdictions, including Canada, China, Europe, India, Singapore and South Korea.

Proteomics International said continued patent development supports its broader commercialisation strategy for PromarkerEndo and provides a foundation for potential partnerships and licensing opportunities.

Management Commentary on Commercialisation Pathway

Proteomics International CEO and Managing Director David Morris said the acceptance of the Australian patent represents further validation of the novelty and commercial potential of PromarkerEndo.

Mr Morris said securing protection in the company’s home Jurisdiction represents another step in its global commercialisation strategy.

The company highlighted Australia as an important market opportunity as Demand increases for non-invasive diagnostic technologies focused on improving patient outcomes and reducing healthcare costs.

Company Focus on Precision Diagnostics

Proteomics International is a medical technology company focused on precision diagnostics and bio-analytical services.

The company’s development activities are based around proteomics, which involves studying the structure and function of proteins at an industrial scale.

Through its Promarker platform, Proteomics International develops diagnostic tools designed to identify protein-based markers associated with disease conditions.

Investor Takeaway

Proteomics International’s latest update marks a further intellectual property milestone for its PromarkerEndo endometriosis diagnostic technology, with Australian patent acceptance adding to existing protection in Japan and the United States.

Investors may continue watching further patent approvals across international markets, development activities for PromarkerEndo, and the company’s progress towards potential commercialisation pathways, partnerships and licensing opportunities.